Last reviewed · How we verify
VarilrixTM
VarilrixTM is a live attenuated vaccine that helps prevent chickenpox.
VarilrixTM is a live attenuated vaccine that helps prevent chickenpox. Used for Prevention of chickenpox.
At a glance
| Generic name | VarilrixTM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by introducing a weakened form of the varicella-zoster virus to the body, which triggers an immune response and builds immunity against chickenpox.
Approved indications
- Prevention of chickenpox
Common side effects
- Injection site pain
- Fever
- Fatigue
Key clinical trials
- Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox (PHASE3)
- Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). (PHASE2)
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VarilrixTM CI brief — competitive landscape report
- VarilrixTM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI